Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Antimitotic Activity of 5-Tertiary Butyl Benzimidazolone

An Erratum to this article was published on 25 January 1958


IN chronic toxicity tests of several derivatives of benzimidazolone, the 5-substituted compounds were well tolerated, with the exception of the 5-tertiary butyl benzimidazolone. This substance caused retardation of growth in rats receiving the standard dose of 500 mgm./kgm./day by stomach tube, with death after 20–25 days of treatment. Hæmatological examination after the onset of the loss in weight revealed a severe anæmia and leukopænia, found at autopsy to be the results of aplasia of the bone marrow. Lymphoid atrophy was also seen; but other tissues showed no change, except for the presence in various organs of large numbers of mitotic figures.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations


Rights and permissions

Reprints and Permissions

About this article

Cite this article

STOERK, H., ARISON, R. & HAWKINS, J. Antimitotic Activity of 5-Tertiary Butyl Benzimidazolone. Nature 180, 1428–1429 (1957).

Download citation

  • Issue Date:

  • DOI:


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing